IP Library Granted Patent US 9,718,848
Granted Patent B2
US 9,718,848 · App. 15/368,921 · Granted Aug 1, 2017

Compounds

Inventors: Jerry Adams (Collegeville, PA); Kevin J. Duffy (Collegeville, PA); Yiqian Lian (Collegeville, PA)
Assignee: GlaxoSmithKline Intellectual Property Development Limited
C07F9/65746A61K39/39C07H21/02C07H21/04A61K2039/55511
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,718,848
App. No.
15/368,921
Granted
Aug 1, 2017
Kind
B2
Abstract

A compound of Formula (I) wherein Y 1 , Y 2 , X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , and R 9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.

Claims (64)

1. A compound of Formula (IV):

wherein:

X 31 is S;

X 32 is O;

R 31 is OH and R 32 is NH 2 or R 31 is NH 2 and R 32 is H;

R 33 is OH and R 34 is NH 2 or R 33 is NH 2 and R 34 is H;

R 35 is selected from: F, OH, and OC(O)R 37 ;

R 36 is selected from: F, OH, and OC(O)R 37 ;

provided: at least one of R 35 and R 36 is F; and

R 38 and R 39 are independently selected from: H, CH 2 OC(O)R 37 , CH 2 OCO 2 R 37 , CH 2 CH 2 SC(O)R 37 , and CH 2 CH 2 SSCH 2 R 37 ;

where R 37 is selected from: aryl, heteroaryl, heterocycloalkyl, cycloalkyl, C 1-20 alkyl and C 1-20 alkyl substituted with one to 5 substituents independently selected from: aryl, cycloalkyl, hydroxy and F;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 35 is selected from: F and OH; and

R 36 is selected from: F and OH;

provided: at least one of R 35 and R 36 is F.

3. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 35 is OH; and

R 36 is F.

4. A compound of claim 1 selected from:

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt thereof;

a pharmaceutically acceptable salt of

a pharmaceutically acceptable salt of

a pharmaceutically acceptable salt of

or a pharmaceutically acceptable salt thereof; and

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more of pharmaceutically acceptable excipients.

6. A method of treating a disease state selected from: inflammation, allergic diseases, autoimmune diseases, human immunodeficiency virus (HIV), infectious diseases, cancer, and pre-cancerous syndromes, in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound of Formula IV, or a pharmaceutically acceptable salt thereof, as described in claim 1 .

7. The method of claim 6 wherein the mammal is a human.

8. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and an antigen or antigen composition.

9. A vaccine composition comprising an antigen or antigen composition and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

10. An immugenic composition comprising an antigen or antigen composition and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

11. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and one or more immunostimulatory agents.

12. A method of treating a disease selected from: HBV, HCV, influenza, skin warts, multiple sclerosis, and allergic inflammation, in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described in claim 1 .

13. A compound having the following structure:

or a pharmaceutically acceptable salt thereof.

14. A compound which is:

15. A pharmaceutically acceptable salt of a compound of claim 13 which is:

16. A compound of claim 13 which is:

or a pharmaceutically acceptable salt thereof.

17. A compound which is:

18. A pharmaceutically acceptable salt of a compound of claim 13 which is:

19. A compound of claim 13 which is:

or a pharmaceutically acceptable salt thereof.

20. A compound of which is:

21. A pharmaceutically acceptable salt of a compound of claim 13 which is:

22. A pharmaceutical composition comprising a compound of claim 13 , or a pharmaceutically acceptable salt thereof, and one or more of pharmaceutically acceptable excipients.

23. A method of treating a disease state selected from: inflammation, allergic diseases, autoimmune diseases, human immunodeficiency virus (HIV), infectious diseases, cancer, and pre-cancerous syndromes, in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, as described in claim 13 .

24. The method of claim 23 wherein the mammal is a human.

25. A composition comprising a compound of claim 13 , or a pharmaceutically acceptable salt thereof, and an antigen or antigen composition.

26. A vaccine composition comprising an antigen or antigen composition and a compound of claim 13 , or a pharmaceutically acceptable salt thereof.

27. An immugenic composition comprising an antigen or antigen composition and a compound of claim 13 , or a pharmaceutically acceptable salt thereof.

28. A composition comprising a compound of claim 13 , or a pharmaceutically acceptable salt thereof, and one or more immunostimulatory agents.

29. A method of treating a disease selected from: HBV, HCV, influenza, skin warts, multiple sclerosis, and allergic inflammation, in a human in need thereof, which comprises administering to such human a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, as described in claim 13 .

30. A compound of claim 1 selected from:

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt thereof; and

or a pharmaceutically acceptable salt thereof.

31. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

R 38 and R 39 are H.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2017
From: ADAMS, JERRY LEROY; DUFFY, KEVIN J.; LIAN, YIQIAN
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 041497/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: ADAMS, JERRY LEROY; DUFFY, KEVIN J.; LIAN, YIQIAN
To: GLAXOSMITHKLINE LLC
Reel/Frame 041335/0890 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: GLAXOSMITHKLINE LLC
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
Reel/Frame 041336/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 041337/0889 →
Continuity (7)
Continuation PCTIB2016057265 · Dec 1, 2016
Provisional Application 62332517 · May 6, 2016
Provisional Application 62327579 · Apr 26, 2016
Provisional Application 62299704 · Feb 25, 2016
Provisional Application 62299253 · Feb 24, 2016
Provisional Application 62262668 · Dec 3, 2015
Related Publication 20170158724A1 · Jun 8, 2017